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Abstract
Growth hormone receptor knockout (GHR-KO) mice are long lived with improved
healthspan, making this an excellent model system for understanding biochemical
mechanisms important to cognitive reserve. The purpose of the present study was to
elucidate differences in cognition and glutamatergic dynamics between aged (20-24
month-old) GHR-KO and littermate controls.

Glutamate plays a critical role in

hippocampal learning and memory and is implicated in several neurodegenerative
disorders, including Alzheimer’s disease. Spatial learning and memory were assessed
using the Morris water maze (MWM), while independent dentate gyrus (DG), CA3 and
CA1 basal glutamate, release, and uptake measurements were conducted in isoflurane
anesthetized mice utilizing an enzyme-based microelectrode array (MEA) coupled with
constant potential amperometry.

These MEAs have high temporal and low spatial

resolution while causing minimal damage to the surrounding parenchyma. Littermate
controls performed worse on the memory portion of the MWM behavioral task and had
elevated DG, CA3 and CA1 basal glutamate and stimulus-evoked release compared with
age-matched GHR-KO mice. CA3 basal glutamate negatively correlated with MWM
performance. These results support glutamatergic regulation in learning and memory and
may have implications for therapeutic targets to delay the onset of, or reduce cognitive
decline, in Alzheimer’s disease.
Keywords: healthspan, longevity, biosensor, electrode, Alzheimer’s disease
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1. Introduction
Growth hormone (GH) is secreted by the anterior pituitary gland and binds to its receptor
ubiquitously expressed throughout the mammalian reproductive, muscular, endocrine,
and nervous systems, where it regulates growth and metabolism often mediated through
insulin-like growth factor-I (IGF-1)1. The GH/IGF-1 axis is regarded as an important
regulator in aging such that attenuated signaling increases lifespan2, potentially by
providing protection against cancer, diabetes, and neurodegeneration3. This is supported
by GH receptor knockout (GHR-KO) mice that exhibit increased lifespan (30-36 months)
and improved healthspan (reduced and delayed incidence of neoplasty, protection from
diet-induced nephropathy, and retained cognitive abilities). Furthermore, inhibition of GH
has been shown to increase neuronal differentiation4 and GHR-KO mice have an
approximate 25% increase in total neuron cell density in the cortex.5 However these
benefits come at a concession of decreased size with increased adiposity, similar to Laron
Syndrome6–10.
The increased lifespan of GHR-KO mice make them an excellent model system for
studying age-related cognitive reserve and neurotransmitter regulation in comparison to
littermate controls.

For example, recent data support that GHR-KO mice maintain

hippocampal glutamatergic function from 4-22 months of age, including vesicular
glutamate transporter (VGLUT) 1 (the predominant hippocampal VGLUT located in
classical excitatory terminals11) and 3, glutamate transporter 1 (GLT-1), and the N-methylD-aspartate (NMDA) receptor subtype GluN2B12. Glutamate, the predominant excitatory
neurotransmitter in the mammalian CNS, has a strong prevalence in neocortical and
hippocampal pyramidal neurons; therefore, playing a critical role in learning and
3

memory13. Because of this, glutamate dysregulation has been implicated in age-related
cognitive decline associated with neurodegenerative disorders such as Alzheimer’s
disease13–17.
The purpose of the present study was to elucidate differences in cognition and
glutamatergic dynamics between aged (20-24 month-old) GHR-KO and age-matched
littermate controls. Spatial learning and memory was assessed using the Morris water
maze (MWM) behavioral paradigm18–20. Extracellular glutamate dynamics were studied
in the dorsal hippocampus since this region is important for consolidation and retrieval of
spatial memory21. Glutamate measurements were conducted utilizing an enzyme-based
microelectrode array (MEA) coupled with constant potential amperometry to
independently measure basal glutamate and stimulus-evoked glutamate release, and
uptake in the dentate gyrus (DG), CA3, and CA1 of isoflurane anesthetized littermate
controls and GHR-KO mice. These MEAs have high temporal (4 Hz)22 and low spatial
resolution (50 x 100 µm) while causing minimal damage to the surrounding parenchyma
(50-100 microns)23. The results presented here support the importance of glutamatergic
regulation for learning and memory in the GHR-KO mouse model of successful aging.
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2. Methods

2.1 Animals

Female GHR-KO (20-24 months of age) and age-matched female normal littermate
controls, were produced in a breeding colony maintained at Southern Illinois University
School of Medicine. This colony was established by crossing 129Ola/BALB/c GHR +/breeders24 provided by Dr. John J. Kopchick with mice derived from crosses of C57BL/6J
and C3H/J strains and maintained as a closed colony with inbreeding minimized by
avoiding brother x sister matings25. Protocols for animal use were approved by the
Laboratory Animal Care and Use Committee at Southern Illinois University School of
Medicine. Animals were group housed on a 12:12 hour light: dark cycle, and food and
water were available ad libitum. Each mouse underwent cognitive assessment, in vivo
glutamate recordings, and post mortem histological analysis of brain tissue with the
exception of a loss of two GHR-KO mice that occurred after MWM due to complications
during surgery prior to in vivo electrochemistry. Immediately following in vivo glutamate
recordings, mice were euthanized with an overdose of isoflurane and decapitated. Upon
decapitation, 5 mm tail snips were collected and stored at -80°C until shipment to
TransnetYX®, Inc (Cordova, TN) for genotype verification.

2.2 Chemicals

All chemicals were prepared and stored according to manufacturer recommendations
unless otherwise noted. L-glutamate oxidase (EC 1.4.3.11) was obtained from Cosmo
Bio Co. (Carlsbad, CA) and diluted in distilled, deionized water to make a 1U/µl stock
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solution that was stored at 4°C. Sodium phosphate monobasic monohydrate, sodium
phosphate dibasic anhydrous, 1,3-phenylenediamine dihydrochloride (mPD), sodium
chloride, calcium chloride dehydrate, and hydrogen peroxide (H2O2, 30% in water) were
obtained from Thermo Fisher Scientific (Waltham, MA). L-glutamic acid sodium salt,
potassium

chloride,

bovine

serum

albumin

(BSA),

glutaraldehyde,

dopamine

hydrochloride (DA), L-ascorbic acid (AA), and DPX were obtained from Sigma-Aldrich Co.
(St. Louis, MO). Rabbit polyclonal glial fibrillary acidic protein antibody (GFAP) was
obtained from Dako. Guinea pig polyclonal VGLUT1 antibody was obtained from
Millipore. Biotinylated goat anti-rabbit serum, biotinylated goat anti-guinea pig serum,
avidin-biotin complex (ABC) kit, and VIP peroxidase substrate kit were obtained from
Vector Laboratories.

2.3 Morris water maze
The MWM tests spatial learning and memory by requiring the mouse to utilize visual
clues for locating a static, submerged platform, regardless of the starting quadrant as
previously reported20. The MWM paradigm consists of 5 consecutive learning days with
three, 90 s trials/day and a minimum of 20 min between trials. After two days without
testing, mice are given a single, 60 s probe challenge to test memory. The ANY-maze
video tracking system (Stoelting Co., Wood Dale, IL) records and analyzes duration in
each quadrant, distance traveled, average speed, and path efficiency for the 5 learning
days. Additional parameters analyzed for the single probe trial include the number of
platform crosses, time in annulus 40, latency, distance, and path efficiency to first platform
cross.
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2.4. In Vivo Glutamate Measurements

2.4.1 Enzyme-Based Microelectrode Arrays

Enzyme-based MEAs with platinum (Pt) recording surfaces (Figures 1A & B) were
fabricated, assembled, coated, and calibrated for

in vivo

mouse glutamate

measurements22,26,27. Briefly, one of the R2 MEA Pt sites was coated with an L-glutamate
oxidase, BSA and glutaraldehyde coating solution. BSA and glutaraldehyde increase the
adhesion and crosslink L-glutamate oxidase to the MEA surface. L-glutamate oxidase
causes the enzymatic breakdown of glutamate to α-ketoglutarate and the electroactive
reporter molecule, H2O2. The second Pt recording site (self-referencing or sentinel site)
was coated similar to the glutamate recording site, except L-glutamate oxidase was
omitted from the coating solution; therefore, the sentinel site was unable to enzymatically
generate H2O2 from L-glutamate. A potential of +0.7V vs a Ag/AgCl reference electrode
was applied to the Pt recording surface, resulting in a two electron oxidation of H2O2 and
the current was amplified and digitized by the Fast Analytical Sensing Technology (FAST)
16mkIII (Quanteon, LLC; Nicholasville, KY) electrochemistry instrument.

2.4.2 mPD Electropolymerization

A minimum of 72 hrs after enzyme coating, all Pt recording surfaces were electroplated
with 5 mM mPD in 0.05 M phosphate buffered saline (PBS) 28. FAST electroplating
software applied a potential as a triangular wave with an offset of -0.5V, peak-to-peak
amplitude of 0.25V, at a frequency of 0.05 Hz, for 20 min to create a size exclusion layer
that restricts the passage of AA, DA, uric acid and 3,4-dihydroxyphenylacetic acid.
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2.4.3 Calibration

A minimum of 24 hrs after mPD electropolymerization, each MEA was calibrated in vitro
prior to implantation to generate a standard curve for the conversion of current to
glutamate concentration29.

The Pt recording sites and a glass Ag/AgCl reference

electrode (Bioanalytical Systems, Inc., West Lafayette, IN) were placed in a continuously
stirred solution of 0.05 M PBS (40.0 mL) maintained at 37°C with a recirculating water
bath (Stryker Corp., Kalamazoo, MI). Final beaker concentrations of 250 µM AA, 20, 40,
and 60 µM L-glutamate, 2 µM DA, and 8.8 µM H2O2 were used to assess MEA
performance (Figure 1C). A total of 18 MEAs (13 unique) were used in the present study.
The average ± standard error of the mean (SEM) for glutamate sensitivity was 9.7 ± 1.0
pA/μM (R2 = 0.995 ± 0.003), selectivity ratio of 805 ± 327 to 1, and limit of detection of
0.45 ± 0.26 μM based on a signal-to-noise ratio of 3.

2.4.4 Microelectrode Array / Micropipette Assembly
A glass micropipette (1.0 mm outer diameter, 0.58 mm internal diameter; World Precision
Instruments, Inc., Sarasota, FL) was used to locally apply solutions to the mouse
hippocampal subfields. Glass micropipettes were pulled using a vertical micropipette
puller (Sutter Instrument Co., Novato, CA) and the tip was ‘bumped’ to create an internal
diameter of 12-15 µm. The tip of the micropipette was positioned between the pair of
recording sites and mounted 100 µm above the MEA surface. The micropipettes were
filled with sterile filtered (0.20 µm) 70 mM KCl (70 mM KCl, 79 mM NaCl and 2.5 mM
CaCl2, pH 7.4).

Fluid was pressure-ejected from the glass micropipette using a

Picospritzer III (Parker-Hannafin, Cleveland, OH), with pressure (5-15 psi) adjusted to
8

consistently deliver volumes between 100-200 nl over 1-2 s intervals. Ejection volumes
were monitored with a stereomicroscope (Luxo Corp., Elmsford, NY) fitted with a
calibrated reticule30.

2.4.5 Reference Electrode

A Ag/AgCl reference electrode was prepared by stripping 5 mm of Teflon from each end
of a silver wire (200 μm bare, 275 μm coated; A-M Systems, Carlsberg, WA). One of the
stripped ends was soldered to a gold-plated test connector (Newark element14 Chicago,
IL) and the other end was coated with AgCl by placing the tip of the stripped sliver wire
(cathode) into a 1 M HCl plating bath saturated with NaCl containing a stainless steel wire
(anode) and applying +9 V DC using a power supply to the cathode versus the anode for
15 min.

2.5 In Vivo Anesthetized Recordings

At least one week following the MWM probe challenge, mice were anesthetized using
1.5-2.0% isoflurane (Abbott Lab, North Chicago, IL) from a calibrated vaporizer (Parkland
Scientific, Inc., Coral Springs, FL) and prepared for in vivo electrochemical recordings
(Hascup & Hascup, 2014). The mouse was placed in a stereotaxic frame (David Kopf
Instruments, Tujunga, CA) fitted with a mouse anesthesia mask and body temperature
was maintained at 37°C with a hydrothermal pad connected to a recirculating water bath.
A craniotomy was performed to access the DG (AP: -2.0, ML: ± 1.0, DV: -2.2 mm), CA3
(AP: -2.0, ML: ± 2.0, DV: -2.2 mm), and CA1 (AP: -2.0, ML: ± 1.0, DV: -1.7 mm) from
Bregma based on the coordinates of Paxinos and Franklin31. A Ag/AgCl reference wire
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was implanted in the right cortex, remote from the recording area. The MEA / micropipette
assembly was lowered into the DG, CA3, or CA1 (hippocampal subfield and hemisphere
randomly assigned for each mouse) using a microdrive (Narishige International, East
Meadow, NY) attached to the electrode holder of the stereotaxic arm. Constant potential
amperometry (4Hz) was performed using the FAST16mkIII and FAST software for multichannel simultaneous recordings32. MEAs were allowed to reach a stable baseline for 60
min, at which time basal glutamate measures were taken (ten second average) followed
by pressure ejection studies. All values for pressure ejections refer to changes versus
baseline. After pressure ejection studies, brains were removed and fixed in 4%
paraformaldehyde followed by 0.1 M phosphate buffer containing 30% sucrose for at least
24 hours before cryosectioning for immunohistochemistry (45 μm).

2.6 Immunohistochemical Staining and Semiquantification

Immunohistochemistry in the hippocampus was performed using rabbit polyclonal GFAP
(1:2000) or guinea pig polyclonal VGLUT1 antibody (1:1,000). Briefly, primary antibodies
were applied to serial sections taken for every sixth section from the hippocampus based
on our previous protocols33. Endogenous peroxidase activity was quenched by treating
sections with 10% H2O2 in 20% methanol for 10 minutes. Sections were then
permeabilized in TBST (Tris-buffered saline with 0.25% TritonX-100) following treatment
for 20 minutes with sodium metaperiodate. Non-specific binding was controlled by
incubation in 10% normal goat serum for 1 hour. Sections were then incubated overnight
in the primary antibody at room temperature. The next day, sections were incubated for
1 hour with the secondary antibody (1:200; biotinylated goat anti-rabbit serum or
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biotinylated goat anti-guinea pig serum) and 1 hour with the ABC kit. The reaction was
developed using the VIP peroxidase substrate kit to enhance the reaction and produce a
color stain. This reaction was stopped using 0.1 M phosphate buffer, and the sections
were mounted on glass slides, dehydrated, and cover-slipped with DPX. To control for
staining intensity, staining of all sections for each antibody were conducted on the same
day, and developed with VIP for the same amount of time (GFAP: 3 minutes, VGLUT-1:
2 minutes).
Staining intensity of GFAP and VGLUT-1 in the hippocampus was determined using
National Institutes of Health Image J Software 1.48 to measure a gray scale value within
the range of 0–256, where 0 represents white and 256 black. A template for the DG, CA3,
and CA1 subregions of the hippocampus was created and used on all brains similarly,
and images were captured with a Nikon Eclipse E-600 microscope equipped with an
Olympus-750 video camera system, and a Dell Pentium III computer. Measurements
were performed blinded and approximately 6 sections were averaged to obtain 1 value
per subject. Staining density was obtained when background staining was subtracted
from mean staining intensities on every sixth section through the hippocampus.

2.7 Data Analysis

The FAST16MkIII electrochemical instrument and FAST software saves amperometric
data, time and pressure ejection events for all Pt recording sites. Calibration data, in
conjunction with a MATLAB (MathWorks, Natick, MA) graphic user interface program
developed by Jason Burmeister Consulting, LLC (Version 6.1) was used to calculate
basal glutamate and 70 mM KCl-evoked glutamate release and uptake. To determine
11

extracellular glutamate concentration, the sentinel site current (pA) was subtracted from
the glutamate recording site current (pA) and divided by the slope (pA/µM) obtained
during the calibration32,34–36. Basal glutamate was calculated by taking a 10 s baseline
average prior to start of pressure ejection in the DG, CA3, and CA1. For stimulus-evoked
glutamate studies, five reproducible signals were obtained in each hippocampal subfield.
These signals were then averaged into a single data point for each hippocampal subfield
per mouse for comparison between genotypes. Glutamate uptake followed first-orderrate kinetics; therefore the uptake rate constant (k−1) was calculated as the logarithmic
slope of glutamate concentration versus time (s −1) estimated by use of regression
analyses (R2≥0.9). Because of different cell types and afferent inputs, hippocampal
subfields were analyzed independently. Prism software (GraphPad Software, Inc., La
Jolla, CA) was used for all statistical analyses. A two-way Analysis of Variance (ANOVA)
with Tukey’s multiple comparison’s post-hoc test was used to analyze MWM training data.
An unpaired, two-tailed Student’s t-test was used to analyze MWM probe,
electrochemical, and immunohistochemical data in each hippocampal subfield.
Comparisons between MWM and glutamate electrochemical data were established
using Pearson correlation. Outliers, determined using Grubbs’ test with alpha = 0.05,
were removed prior to analysis (no more than one per genotype). Data are represented
as mean ± SEM and significance was defined as p<0.05.
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3. Results
3.1 MWM Training and Probe Challenge
Learning and memory was assessed using an 8 day MWM behavioral paradigm as
described in section 2.420. A significant increase by the fifth training day, relative to the
first training day, in the path efficiency (F(4,72) = 13.72; p<0.0001) to reach the hidden
escape platform was observed for the littermate controls and GHR-KO mice with no
differences observed between the two genotypes on any day (Figure 2A); indicating that
both genotypes were able to consolidate memories and there were no learning-related
genotypic differences. During the probe challenge littermate controls took a less efficient
path (0.16 ± 0.04; F(9,9) = 2.844; p = 0.0280) to first platform entry compared to GHRKO mice (0.37 ± 0.07, respectively); indicating littermate controls had impaired memory
(Figure 2B). Representative probe challenge tracks for littermate controls and GHR-KO
mice are shown in figures 2C & D, respectively.
3.2 Basal Glutamate
Prior to stimulus-evoked glutamate release, basal glutamate measures were assessed in
each of the hippocampal subfields. Littermate control basal glutamate (Figure 3A) was
elevated compared with GHR-KO mice in the DG (2.6 ± 0.5 µM, 0.9 ± 0.3 µM; F(6,6) =
3.582; p = 0.0099), CA3 (3.1 ± 0.4 µM, 1.2 ± 0.4 µM; F(6,6) = 1.232; p = 0.0029) and CA1
(4.3 ± 0.8 µM, 1.2 ± 0.5 µM; F(7,6) = 3.134; p = 0.0055). A negative correlation (r = 0.5619; p = 0.0365) was observed between CA3 basal glutamate and path efficiency to
first platform entry during the MWM probe trial (Figure 3B).
3.3 Stimulus-Evoked Glutamate Release
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We locally applied consistent volumes of 70 mM KCl to littermate controls and GHR-KO
mice in the DG (158 ± 7 nl, 147 ± 4 nl; F(9,7) = 3.555; p = 0.2008), CA3 (152 ± 5 nl, 155
± 10 nl; F(9,7) = 2.447; p = 0.8040), and CA1 (149 ± 6 nl; 153 ± 5 nl; F(9,6) = 1.560; p =
0.6239) to evoke glutamate release (Figure 4A). As shown in Figure 4B, local application
of 70 mM KCl elicited robust, reproducible glutamate signals in the CA3 of littermate
controls and GHR-KO mice. These glutamate signal patterns were observed in all three
hippocampal subfields studied. The average maximal stimulus-evoked glutamate release
was significantly elevated in the littermate controls versus GHR-KO mice in the DG (4.9
± 1.0 µM, 2.3 ± 0.5 µM; F(9,7) = 3.984; p = 0.0452), CA3 (9.1 ± 0.9 µM, 3.7 ± 0.5 µM;
F(9,7) = 4.772; p = 0.0002) and CA1 (3.7 ± 0.6 µM, 2.0 ± 0.2 µM; F(9,6) = 12.91; p =
0.0332) as shown in Figure 4C. No statistical differences between stimulus-evoked
glutamate uptake was observed between the littermate controls and GHR-KO mice in DG
(0.4 ± 0.2 µM/sec, 0.7 ± 0.2 µM/sec; F(8,7) = 1.647; p = 0.3392), CA3 (2.0 ± 0.5 µM/sec,
1.1 ± 0.3 µM/sec; F(9,7) = 3.263; p = 0.1470), or CA1 (0.6 ± 0.2 µM/sec, 0.7 ± 0.3 µM/sec;
F(8,7) = 2.673; p = 0.4228) (Figure 4D).
3.4 Histological Assessment
Littermate control GFAP (Figure 5A) was decreased compared with GHR-KO mice in the
DG (10.6 ± 1.3, 15.3 ± 1.3; F(8,7) = 1.121; p = 0.0236), CA3 (12.7 ± 0.5, 15.9 ± 1.0; F(7,8)
= 3.089; p = 0.0096), and CA1 (8.7 ± 0.6, 12.5 ± 0.8; F(7,8) = 1.684; p = 0.0016).
Representative images of GFAP staining in whole hippocampus for littermate controls
and GHR-KO mice are shown in Figures 5B and C, respectively. Magnified images of
the DG, CA3, and CA1 for littermate controls (5D, F, and H, respectively) and GHR-KO
mice (Figures 5E, G, and I, respectively) are presented. We observed hippocampal brain
14

region and genotype dependent changes in VGLUT1 staining. Littermate controls
VGLUT1 (Figure 6A) was decreased compared to GHR-KO mice in the DG (4.5 ± 0.6,
12.3 ± 0.8; F(7,8) = 1.633; p <0.0001), no change in the CA3 (6.8 ± 0.8, 8.7 ± 1.0; F(7,8)
= 1.163; p = 0.1476), and increased in the CA1 (8.2 ± 0.9, 5.2 ± 0.5; F(8,7) = 3.997; p =
0.0133).

Representative images of VGLUT1 staining in the DG, CA3, and CA1 of

littermate controls and GHR-KO mice are shown in Figures 6B-G.

4. Discussion
The glutamatergic system plays an important role in age-related cognitive decline and
cognitive disorders, and that tight regulation of glutamate is essential for normal
brain/cognitive function. Generally, the two major means of controlling both tonic and
phasic glutamate neurotransmission are through glutamate release and uptake. Under
normal conditions, glutamate release is primarily accomplished through depolarization of
glutamatergic neurons, which can be identified by the presence of VGLUTs located at the
terminals. Glial cells, composed of astrocytes and microglia, are predominantly
responsible for clearance of glutamate from the extracellular space mediated through
surface expression of excitatory amino acid transporters (EAATs). One EAAT, Glt-1
(EAAT2 in humans), is responsible for ~90% of glutamate clearance from the extracellular
space37. Additionally, Glt-1 surface expression and function decrease with age, possibly
leading to excitotoxicity, which may be exacerbated in age-related cognitive disorders,
further supporting the importance of proper glutamate system maintenance for cognitive
retention in advanced age17. We have previously reported on age-related changes in
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glutamatergic markers, including elevated mRNA expression of GLT-1 and retained
VGLUT1 levels in the hippocampus of long lived GHR-KO mice compared to agematched littermate controls12.

In the present study, we examine cognition and

glutamatergic neurotransmission dynamics to elucidate the role of glutamate in GHR-KO
mice that exhibit enhanced cognition in old age compared to age-matched littermate
controls.
Our MWM data supports that 20-24 month-old littermate controls and GHR-KO mice learn
to locate the hidden escape platform, indicating no differences in memory consolidation.
However, after a 48 hour delay, littermate controls present with impaired memory retrieval
compared to GHR-KO mice during the probe challenge of the task. While it is well known
that memory retention declines with age in mice38,39, previous studies utilizing the
inhibitory avoidance, open field, and MWM tasks indicate memory retrieval in GHR-KO
mice does not decline with age40–42. This may be the result of more stringent regulation
of the glutamate system in the hippocampus, as supported by our previous findings 12.
Therefore, a possible explanation for improved memory retrieval in GHR-KO mice is that
they experience delayed aging thereby postponing the onset of cognitive decline40.
The dorsal hippocampus is important for consolidation and retrieval of spatial memory
during the MWM task21. Hippocampal inhibition of the EAATs, and therefore decreased
glutamate clearance, has been shown to induce long term depression (LTD) mediated
through elevated extrasynaptic glutamate binding to the GluN2B-NMDA receptor
subtype43 and negatively impacting cognition. In support of this, we observed a negative
correlation between CA3 basal glutamate and path efficiency to first platform entry on the
MWM task, however, this correlation was not observed with DG or CA1 basal glutamate.
16

This may be due to of the importance of mossy fiber projections to the CA3 subfield for
memory consolidation and retrieval in spatial navigation tasks44,45.

Therefore, the

increased availability of basal glutamate to activate GluN2B in the CA3 may contribute to
the cognitive decline observed in littermate controls while the corollary is true in the GHRKO mice. Furthermore, we observed elevated GFAP staining in the hippocampus of GHRKO mice indicating an increase in glia, which likely contributed to the overall decrease in
glutamatergic tone in these mice.
We observed decreased evoked release of glutamate in GHR-KO mice in all three
hippocampal subregions examined compared to age-matched littermate controls. This
may be explained by previous reports12 of an age-related decrease in VGLUT1 mRNA
levels from whole hippocampus in littermate controls, but not GHR-KO mice.

Further

evaluation of 20-24 month old female GHR-KO and littermate control mice presented in
the current manuscript using histological techniques revealed hippocampal subregion
dependent changes in VGLUT1. However, this is contradictory to our evoked glutamate
release data where littermate controls exhibited elevated glutamate release compared to
GHR-KO mice. This likely indicates a disconnect between the number of glutamate
terminals (VGLUT1) and the inherent excitability of the neurons (stimulated release). It is
also possible that the anesthetic used during our glutamate recordings (isoflurane)
preferentially suppressed KCl-evoked glutamate release in GHR-KO mice. However, this
is highly unlikely because isoflurane dosage was kept consistent (1.5-2.0%) between
mice. Furthermore, GHR-KO mice have a higher metabolic rate than their littermate
controls and therefore would metabolize isoflurane more quickly, if anything, thereby
having less anesthetic-related alterations.
17

Since basal glutamate levels are regulated by a combination of continuous release and
uptake, we are not able to directly measure clearance kinetics as we can with stimulusevoked glutamate release. However, we did not observe any difference in 70 mM KClevoked glutamate uptake between genotypes in any of the hippocampal subfields studied
despite a significant difference in GFAP levels, possibly because there was sufficient
GLT-1 present in close proximity and functioning adequately enough to quickly clear
evoked glutamate released from both genotypes. We observed significantly more GFAP
in all three hippocampal subregions examined in GHR-KO mice compared to littermate
controls. It is possible that the increased energy demands of GHR-KO mice compared to
littermate controls46 may lead to an increase in astrocytes (the main location of glycogen
in the brain) to ensure that the brain has sufficient energy, with glutamate uptake into
astrocytes contributing to the store of available energy 47,48. While an increase in GFAP
does not always indicate elevated GLT-1, our previous data indicate elevated GLT-1
mRNA in GHR-KO hippocampus12. Since GLT-1 accounts for 90% of glutamate uptake37,
a decrease in this transporter may slow glutamate clearance, leading to the elevated
basal glutamate observed in the littermate controls. However, it should be noted that
mRNA levels do not necessarily correspond to protein levels or even surface expression
and it is possible that experimental design limitations may have contributed to this
discrepancy between elevated GFAP and GLT-1, but no differences in the uptake rate of
evoked release of glutamate.

First, EAATs are electrogenic and membrane

depolarization slows glutamate uptake49. Second, isoflurane, the anesthetic used in this
study, increases glutamate uptake through GLT-150.
18

Although, the amount of stimulus

and anesthetic were consistent in all mice, it is possible that the combination of these two
phenomena could alter GLT-1 such that their effects overshadow differences in
transporter number when measured with our recording technique.
Additionally, glucocorticoids may contribute to elevated basal and stimulus-evoked
glutamate release in the littermate control mice. Glucocorticoids have the potential to
increase basal glutamate levels in the hippocampus and impair memory through binding
of glutamate to the GluN2B containing NMDA receptor51, which may also be affected by
isoflurane. While Huack and colleagues52 demonstrated there was no difference in
corticosterone levels in 4-5 month old female GHR-KO and littermate control mice under
stressed and non-stress conditions, to date glucocorticoid levels have not been examined
in aged female GHR-KO mice.

Previous studies support that glucocorticoid levels

increase as female mice age contributing to age-related bone loss53. Considering GHRKO mice are a model of delayed aging, it goes to reason that glucocorticoid levels may
be increased in littermate controls compared to GHR-KO mice, potentially contributing to
the elevated extracellular glutamate observed in this study.
In summary, we have demonstrated that littermate controls have impaired cognition and
hyperglutamatergic signaling in the DG, CA3, and CA1 hippocampal subfields compared
to GHR-KO mice. Cognitive performance on the MWM behavioral task was predicted by
CA3, but not DG or CA1, basal glutamate and elevated GFAP observed in GHR-KO mice
may be neuroprotective by contributing to decreased basal glutamate levels. Taken
together, these data and our recent reports of elevated evoked glutamate release in the
hippocampus of APP/PS1 mice, a model of Alzheimer’s disease 20, support an
overarching theme whereby elevated hippocampal glutamate is associated with cognitive
19

impairment and maintenance of the glutamatergic system throughout life is essential for
the preservation of cognition in aging and age-related neurodegenerative disorders.
Furthermore, these data support the importance of glutamatergic regulation for learning
and memory in the GHR-KO mouse model of successful aging that may relate to cognitive
resilience and could have implications as therapeutic targets to delay the onset of, or
reduce cognitive decline, in several diseases and disorders, including Alzheimer’s
disease.
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Figure Legends:
Figure 1: MEA and In Vitro Calibration. A) Image of the R2 MEA used for anesthetized
recordings with a ruler for scale comparison and (B) magnified tip depicting 2 Pt recording
sites, each measuring 50 x 100 µm with 100 µm spacing between sites. C) A typical MEA
in vitro calibration measuring the change in current on a glutamate measuring site (black)
and a sentinel recording site (gray) with the addition of multiple analytes, as indicated (↓).
The addition of interferents such as AA and DA produced no current change on either site
since they are blocked by the mPD exclusion layer. Three glutamate additions showed
a stepwise increase of current on the glutamate oxidase / BSA / glutaraldehyde site, but
no response on the BSA / glutaraldehyde sentinel site. The addition of H 2O2 produced a
similar increase of current on both recording sites demonstrating equivalent functionality.
Figure 2: Memory Impairment in Littermate Controls. MWM training sessions
indicates path efficiency (A) to locate the hidden platform was significantly increased over
time for littermate controls and GHR-KO mice (n=10 per group). By the fifth training
session both genotypes took similar durations and distances to reach the platform
indicating comparable learning. Two-way ANOVA indicates a significant (p<0.001) effect
of training day. **p<0.01, ***p<0.001 vs GHR-KO training day 1 and §§§§p<0.0001 vs
littermate control training day 1 based on a Tukey’s multiple comparison post-hoc. MWM
probe challenge indicates littermate controls took a less efficient path (B) to first platform
entry compared to GHR-KO mice. Two-tailed Student’s t-test (n = 10 mice per group),
*p<0.05. Representative MWM probe tracks from littermate controls (C) and GHR-KO
mice (D). The small circle represents the previous location of the hidden escape platform
while the circle surrounding the platform represents the annulus 40.
Figure 3: Elevated CA3 Basal Glutamate Predicts MWM Impairments. A) Bar graphs
depicting elevated basal glutamate in all hippocampal subfields of littermate controls
compared to GHR-KO mice. Two-tailed Student’s t-test (n = 7-8 mice per group)
**p<0.01. B) Correlation of CA3 basal glutamate with MWM probe path efficiency to first
platform entry for littermate controls (open circles) and GHR-KO mice (dark squares).
Dashed line represents the least squares regression.
Figure 4: Stimulus-Evoked Glutamate Release and Uptake. A) Bar graph depicting a
similar range of 70 mM KCl (stimulus) was used to elicit glutamate release in all
hippocampal subfields of both mouse genotypes. B) Representative traces of local
application (↑) of 70 mM KCl-evoked glutamate release in the CA3 of littermate controls
(top, gray) and GHR-KO (bottom, black) mice. C) Bar graphs of average maximal evoked
glutamate was elevated in all hippocampal subfields of littermate controls compared to
GHR-KO mice. D) Glutamate uptake rate was not significantly different between
genotypes in any of the 3 hippocampal subfields. Two-tailed Student’s t-test (n = 7-10
mice per group), *p<0.05, ***p<0.001.
Figure 5:
Hippocampal GFAP Levels. Histological staining of GFAP in the
hippocampus of littermate controls and GHRKO mice. A) Bar graph of GFAP average
mean density was elevated in all hippocampal subfields of GHR-KO mice compared to
littermate controls. Two-tailed Student’s t-test (n = 8-9 mice per group),*p<0.05, **p<0.01.
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Representative images of GFAP staining in whole hippocampus for littermate controls (B)
and GHR-KO mice (C) (scale bar is 100 µm). Representative magnified images of
littermate control and GHR-KO mice DG (D, E, respectively), CA3 (F, G, respectively),
and CA1 (H, I, respectively) (scale bar is 50 µm).
Figure 6: Hippocampal VGLUT1 Levels. Histological staining of VGLUT1 in the
hippocampus of littermate controls and GHRKO mice. A) Bar graph of VGLUT1 average
mean density in littermate controls was decreased compared to GHR-KO mice in the DG,
no change in the CA3, and increased in the CA1. Two-tailed Student’s t-test (n = 8-9 mice
per group),*p<0.05, ****p<0.0001. Representative images of littermate control and GHRKO mice DG (B, C, respectively), CA3 (D, E, respectively), and CA1 (F, G, respectively).
Scale bar is 25 µm.
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